-
Immunicum is advancing a novel immuno-oncology approach to treat solid tumors through its lead program ilixadencel
Immunicum is listed on NASDAQ Stockholm under the ticker IMMU
Tweets by @Immunicum
Tweets by ImmunicumPress Releases
Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Gastrointestinal Stromal Tumors (GIST) in Cancer Immunology, Immunotherapy
16 Jun 2020Immunicum AB (publ) Announces Advancement to a Non-Staggered Inclusion Phase in the Phase Ib/II ILIAD Combination Trial
15 Jun 2020Immunicum AB (publ) Announces Appointment of Peter Hein as Interim Chief Financial Officer
13 May 2020
News
-
ASCO Post Article / Off-the-Shelf Dendritic Vaccine Shows Benefit in Kidney Cancer
12 Mar 2020 -
RedEye Fight Cancer Seminar Presentation
10 Mar 2020 -
Article in BioStock / Immunicum’s Advancements with Ilixadencel
26 Feb 2020 -
Immunicum Article in BioStock
12 Feb 2020 -
RedEye Interview with COO, Sijme Zeilemaker
12 Feb 2020
About us
Developing innovative cancer immunotherapies
Immunicum is advancing a novel cell-based approach to target solid tumors.
Learn more
